R&D Big pharma places big bets on antibody-drug conjugates Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
